Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC101 TIL in r/r Gastrointestinal Tumors
NCT04960072Phase 1Recruiting
- Sponsor
- Juncell Therapeutics
- Start
- Jun 2021
- Primary completion
- Dec 2027
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nolgileucel in gastrointestinal tumor, sponsored by Juncell Therapeutics. Primary endpoints: Objective Response Rate up to 36 months and Progression-Free Survival up to 36 months. Started Jun 2021; status: recruiting.
02
Drugs
nolgileucel
03
Conditions
gastrointestinal tumor
Beyond the preview
Go deeper on NCT04960072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04960072.